Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson’s disease models
Linhui Julie Su(Whitehead Institute for Biomedical Research), Susan Lindquist(Howard Hughes Medical Institute), Tiago F. Outeiro(German Center for Neurodegenerative Diseases), Guy A. Caldwell(University of Alabama), Pavan K. Auluck(Harvard University), Shusei Hamamichi(University of Alabama), Kim A. Caldwell(University of Alabama), Daniel F. Tardiff(C4 Therapeutics (United States)), Kathryn J. Hill(Garvan Institute of Medical Research), J. Michael McCaffery(Johns Hopkins University), Antony A. Cooper(University of Missouri–Kansas City), Joshua A. Kritzer(Tufts University), Jean‐Christophe Rochet(Purdue University West Lafayette), Katherine E. Strathearn(Purdue University West Lafayette), Esti Yeger‐Lotem(Ben-Gurion University of the Negev), George W. Bell(Whitehead Institute for Biomedical Research), Fang Liu(Purdue University West Lafayette), Ernest Fraenkel(Massachusetts Institute of Technology), Songsong Cao(University of Alabama)
Cited by 176